Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
XOMA Royalty Corporation - Common Stock
(NQ:
XOMA
)
22.83
-0.82 (-3.47%)
Streaming Delayed Price
Updated: 12:37 PM EST, Feb 10, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Price and Volume
Detailed Quote
Volume
91,040
Open
23.42
Bid (Size)
22.76 (400)
Ask (Size)
23.08 (100)
Prev. Close
23.65
Today's Range
22.75 - 23.43
52wk Range
18.35 - 39.92
Shares Outstanding
11,782,723
Dividend Yield
N/A
Intraday
1 Week
1 Month
3 Month
1 Year
3 Year
5 Year
Top News
More News
XOMA Royalty Announces Closing of Tender Offer and Completed Acquisition of Generation Bio, Inc.
February 09, 2026
Generation Bio Stockholders Received $4.2913 Per Share in Cash Plus a Contingent Value Right
From
XOMA Royalty Corporation
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
January 20, 2026
From
Pomerantz LLP
Via
GlobeNewswire
Performance
YTD
-18.4%
-18.4%
1 Month
-14.8%
-14.8%
3 Month
-31.8%
-31.8%
6 Month
-16.2%
-16.2%
1 Year
-13.3%
-13.3%
More News
Read More
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
January 13, 2026
From
Pomerantz LLP
Via
GlobeNewswire
LAVA Therapeutics Stock Slips 9% Pre-Market – Here’s Why The Company Canceled Its Shareholder Meeting
↗
September 30, 2025
Via
Stocktwits
XOMA Royalty Announces CFO Transition
January 12, 2026
From
XOMA Royalty Corporation
Via
GlobeNewswire
Unusual volume stocks in Wednesday's session
↗
January 07, 2026
Via
Chartmill
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
January 06, 2026
From
Pomerantz LLP
Via
GlobeNewswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of XOMA Royalty Corporation - XOMA
December 30, 2025
From
Pomerantz LLP
Via
GlobeNewswire
XOMA Royalty and Takeda Execute Strategic Royalty Sharing Transaction and Amend Existing Agreement for Mezagitamab
December 30, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
December 22, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Enters into Agreement to Acquire Generation Bio
December 15, 2025
From
Generation Bio Co.; XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Corporation: A Deep Dive into a Biotech Royalty Aggregator (12/13/2025)
December 13, 2025
Via
PredictStreet
Topics
Intellectual Property
XOMA Royalty Announces Closing of Transaction to Acquire Mural Oncology plc
December 05, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of Acquisition
December 05, 2025
From
Mural Oncology plc
Via
GlobeNewswire
Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA Royalty
November 26, 2025
From
Mural Oncology plc
Via
GlobeNewswire
XOMA Royalty Announces Closing of Transactions to Acquire LAVA Therapeutics N.V.
November 21, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Reports Third Quarter and Year to Date 2025 Financial Results and Highlights Recent Business Achievements
November 12, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
Mural Oncology Announces that Mural Shareholders Approve the Proposed Acquisition by XRA 5 Corp., a Wholly Owned Subsidiary of XOMA Royalty
October 24, 2025
From
Mural Oncology plc
Via
GlobeNewswire
LAVA Therapeutics Stock Drops After Amended Deal With XOMA Royalty
↗
October 17, 2025
Via
Stocktwits
XOMA Royalty and LAVA Therapeutics Announce Amendment to Purchase Agreement
October 17, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics N.V.
Via
GlobeNewswire
Turnstone Biologics: A $100 Dream Collides with a $0.34 Reality
October 17, 2025
Via
MarketMinute
Topics
Intellectual Property
Workforce
XOMA Royalty Extends Tender Offer to Acquire LAVA Therapeutics N.V.
October 02, 2025
From
XOMA Royalty Corporation; LAVA Therapeutics
Via
GlobeNewswire
XOMA Royalty Declares Quarterly Preferred Stock Dividends
September 22, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty Announces Closing of Tender Offer for HilleVax, Inc.
September 17, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
XOMA Royalty to Present at H.C. Wainwright 27th Annual Global Investment Conference
September 03, 2025
From
XOMA Royalty Corporation
Via
GlobeNewswire
Frequently Asked Questions
Is XOMA Royalty Corporation - Common Stock publicly traded?
Yes, XOMA Royalty Corporation - Common Stock is publicly traded.
What exchange does XOMA Royalty Corporation - Common Stock trade on?
XOMA Royalty Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for XOMA Royalty Corporation - Common Stock?
The ticker symbol for XOMA Royalty Corporation - Common Stock is XOMA on the Nasdaq Stock Market
What is the current price of XOMA Royalty Corporation - Common Stock?
The current price of XOMA Royalty Corporation - Common Stock is 22.83
When was XOMA Royalty Corporation - Common Stock last traded?
The last trade of XOMA Royalty Corporation - Common Stock was at 02/10/26 12:37 PM ET
What is the market capitalization of XOMA Royalty Corporation - Common Stock?
The market capitalization of XOMA Royalty Corporation - Common Stock is 269.00M
How many shares of XOMA Royalty Corporation - Common Stock are outstanding?
XOMA Royalty Corporation - Common Stock has 269M shares outstanding.
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
